ATTAX

Phase 2

Completed

• Conditions: ocally recurrent or metastatic oesophago-gastric cancer; Locally recurrent or metastatic oesophago-gastric cancer; Cancer - Oesophageal (gullet); Cancer - Stomach

• Registration Number: ACTRN12606000163505
• Lead Sponsor: Australasian Gastro-Intestinal Trials Group A(AGITG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-05-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Histological diagnosis of metastatic or locally recurrent oesophago-gastric cancer (squamous cell, adenocarcinoma or undifferentiated carcinoma)-Any primary oesophago-gastric site (oesophagus, oesophago-gastric junction (OGJ) or stomach)-Unidimensional measurable disease as assessed by CT scan (RECIST criteria)- No prior radiation except for; Adjuvant radiation (radiation alone or chemo-radiation allowed) which must have been completed >12 months ago. For patients who have received adjuvant radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s) unless this site has demonstrated clear progression.Palliative radiotherapy provided there was no concurrent chemotherapy administered, all radiation toxicities have resolved to grade 1 or less and at least 14d has elapsed from the last dose of radiotherapy until the start of chemotherapy in ATTAX. For patients who have received palliative radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s)-No prior chemotherapy agents, except adjuvant chemotherapy > 12 months ago.

Exclusion Criteria

Metastatic disease of the central nervous system.

Study & Design

• Study Type: Interventional
• Study Design: Not specified